Summary
PHARMACELL is a financial institution; the bankruptcy model is trained on trading and manufacturing companies and does not apply here. The 2025 annual accounts show equity of €494,200 and a net result of €223,035. Equity is growing by about 21% per year across the filed financial years. Its solvency ranks better than 32% of 6,676 sector peers (NACE 64, financial year 2025). The company has been active since 2019 and the Belgian Official Gazette contains no insolvency or warning signals.
History
Acts, filings and financial milestones
Next filing, financial year 2026, expected by
2026
26-06
NBB filing
Annual accounts filed
financial year 2025 · abbreviated format
2025
31-12
Financial
Highest result from 2020 to 2025net €223,035 ▲20.7%
Net result €223,035, the highest in the series.
27-06
NBB filing
Annual accounts filed
financial year 2024 · abbreviated format
2024
19-07
NBB filing
Annual accounts filed
financial year 2023 · abbreviated format
2023
24-08
NBB filing
Annual accounts filed
financial year 2022 · abbreviated format · 24 days late
2022
31-12
Financial
Equity above €500,000equity €591,211 ▲20.4%
A profit in every financial year since 2020 builds equity to €591,211.
12-08
NBB filing
Annual accounts filed
financial year 2021 · abbreviated format · 12 days late
2021
30-08
NBB filing
Annual accounts filed
financial year 2020 · abbreviated format · 30 days late
Financial milestoneNBB filingFinancial milestones sit on the financial year-end date, not the filing date.
0 of 1 deed read
About the unread acts
We know of 1 Belgian Official Gazette act for this company. It has not been read yet: what they contain is neither established nor disproved here.
Have them read with priority
Sign in to place this company at the front of the reading queue.